Integrating Palliative and Oncology Care: Past, Present, and Future

Jennifer Temel MD
Professor of Medicine, Harvard Medical School
Co-Director Cancer Outcomes Research & Education, Massachusetts General Hospital
Overview

1. Why did this effort to integrate palliative and oncology care begin?

2. What is the status of the field?

3. What is the future of palliative care for patients with serious cancers?
Why did we start thinking about the possible role for early integration of palliative care for patients with cancer?
The role of palliative care in the hospital or home setting for patients near the end of life had been established for many decades.

**Hospital Setting:** Oncology inpatient teams often requested palliative care consultations for hospitalized patients with difficult to control symptoms or challenging end of life care circumstances.

**Home Setting:** Many patients who died of cancer received hospice services in their home for some period prior to death.
Historical Role of Palliative Care In Oncology

- Inpatient palliative care consultation and hospice left patients and their family members with unmet needs throughout their illness course.
  - Uncontrolled physical and psychological symptoms.
  - Insufficient communication about prognosis, treatment intent, and end of life care.
What is it like for a patient living with a serious cancer, such as metastatic non-small cell lung cancer?

- Symptoms such as shortness of breath or cough
- Side effects of cancer directed therapy
- Increasing symptoms of pain and fatigue when cancer progresses
- Inability to provide self-care

- Diagnosis of metastatic lung cancer
- Anxiety and worry about diagnosis
- Navigating diagnosis and treatment with work/family
- Coping with changes in physical health and functioning
- Facing decisions about end of life care

Death
Historical Role of Palliative Care in Oncology

- Symptoms
- Side effects
- Declining health status
- Admission for pain
- Discontinue cancer therapy
- Anxiety
- Navigating diagnosis and changing relationships
- Planning for EOL

- Inpatient palliative care consultation
- Hospice care at home
Shouldn’t Oncology Clinicians Be Addressing These Issues?

• Of course, oncology is and should be attending to these issues.

• But can we really expect oncology clinicians to be able to do it all?
  • Especially as the complexity of cancer care has increased
Oncology Care Models are Already Complex

- Oncology follow up visits are often booked for 15 or 20 minutes in which clinicians need to:
  - Discuss genetic/molecular testing results
  - Evaluate patients for clinical trials and optimal treatment regimens
  - Enroll patients on clinical trials (including supportive care studies)
  - Assess and manage treatment related toxicities and adjust treatment regimens
What can palliative care do when they are involved early and throughout the illness?

1. Collaborate with oncology to manage patients’ physical and psychological symptoms.
2. Help patient’s cope with living with a serious illness.
3. Engage patients and their family in discussions about the illness, prognosis and (eventually) their end-of-life care preferences.
4. Include the family as recipients of care.

While patients are receiving the best possible cancer treatment
Care Should be Collaborative and Integrated

Oncology Care

Palliative Care

"curative" or "life-prolonging" treatment

symptom control and palliative care
Integrated Palliative and Oncology Care

**Historical Model**
Pros: Less complex  
Con: Palliative care too late

**Integrated Care Model**
Pro: Early palliative care  
Con: Assumes needs are linear

**Personalized Care Model**
Pro: Palliative care based upon needs  
Con: Most complex
Why is Integrated Care Complex?

- Who will provide palliative care?
- What domains will palliative care address?
- Where will palliative care see patients?
- How will patients be scheduled to see palliative care?
- When will palliative care visits be scheduled?
Randomized Trials of Integrated Palliative Care and Oncology Care

**Outpatient Palliative Care Interventions**
- Telephone-based early palliative care model
- In person early palliative care models

**Inpatient Palliative Care Interventions**
- In person early palliative care models
Outpatient Palliative Care Interventions

Telephone-based early palliative care model

In person early palliative care models
Telephone Based Outpatient Early Palliative Care (ENABLE Trials)

- Telephone-based intervention delivered by advanced practice nurses with palliative care training.
- Manualized psycho-education with four weekly structured sessions:
  - Problem solving
  - Communication and social support
  - Symptom management
  - Advance care planning and unfinished business
- Monthly telephone follow up to assess the need for referrals (e.g., to palliative care).
Project ENABLE II

322 patients within 8-12 weeks of a new diagnosis of GI, lung, GU or breast cancer with a prognosis of approximately one year

Outcome Measures

Patient-reported Measures
1. Quality of life
2. Symptoms
3. Depression

Health Service Utilization
1. Completion of advanced directives
2. Referral for palliative care or hospice
3. Days in hospital, intensive care unit and emergency department

ENABLE intervention

Usual Care

Bakitas JAMA 302(7) 2009
ENABLE II – Patient Reported Outcomes

**Figure 2.** Quality of Life, Symptom Intensity, and Mood Scores for All Patients

- **Quality of Life**
  - $p=0.02$

- **Symptom Burden**
  - $p=0.06$

- **Depression**
  - $p=0.02$
## Project ENABLE II

### Full Study Cohort

<table>
<thead>
<tr>
<th>Type of advance directive</th>
<th>Intervention n=161</th>
<th>Usual Care n=161</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Living will</td>
<td>69 (42.9)</td>
<td>76 (47.2)</td>
<td>.50</td>
</tr>
<tr>
<td>Durable power of attorney for health care</td>
<td>68 (42.2)</td>
<td>78 (48.4)</td>
<td>.31</td>
</tr>
<tr>
<td>Do not resuscitate order</td>
<td>13 (8.1)</td>
<td>10 (6.2)</td>
<td>.67</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>referral to hospice</th>
<th>Intervention n=161</th>
<th>Usual Care n=161</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>6 (3.7)</td>
<td>4 (2.5)</td>
<td>.75</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>referral to palliative care</th>
<th>Intervention n=161</th>
<th>Usual Care n=161</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>42 (26.1)</td>
<td>51 (31.7)</td>
<td>.32</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Resource use in prior 3 mo, mean (median) [maximum]</th>
<th>Intervention n=161</th>
<th>Usual Care n=161</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital days</td>
<td>2.8 (0) [25]</td>
<td>3.1 (0) [25]</td>
<td>.06</td>
</tr>
<tr>
<td>Intensive care unit days</td>
<td>0.02 (0) [2]</td>
<td>0.04 (0) [2]</td>
<td>.41</td>
</tr>
<tr>
<td>Emergency department visits</td>
<td>0.27 (0) [3]</td>
<td>0.41 (0) [5]</td>
<td>.37</td>
</tr>
</tbody>
</table>

### Deceased Cohort

<table>
<thead>
<tr>
<th>Type of advance directive</th>
<th>Intervention n=161</th>
<th>Usual Care n=161</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Living will</td>
<td>63 (43.4)</td>
<td>66 (49.2)</td>
<td>.34</td>
</tr>
<tr>
<td>Durable power of attorney for health care</td>
<td>62 (42.8)</td>
<td>67 (50.0)</td>
<td>.23</td>
</tr>
<tr>
<td>Do not resuscitate order</td>
<td>11 (7.6)</td>
<td>7 (5.2)</td>
<td>.47</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>referral to hospice</th>
<th>Intervention n=161</th>
<th>Usual Care n=161</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4 (2.8)</td>
<td>2 (1.5)</td>
<td>.68</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>referral to palliative care</th>
<th>Intervention n=161</th>
<th>Usual Care n=161</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>34 (23.4)</td>
<td>39 (29.1)</td>
<td>.34</td>
</tr>
</tbody>
</table>

* Bakitas JAMA 302(7) 2009

---

**Notes:**
- Type of advance directive: Living will, Durable power of attorney for health care, Do not resuscitate order.
- Referral to hospice and palliative care.
- Resource use in prior 3 mo: Hospital days, Intensive care unit days, Emergency department visits.
Take Home Points From ENABLE

• Patients are really suffering with uncontrolled physical and psychological symptoms that are impacting their quality of life and it is not that hard to make it better.
  • First “proof-of-principal” that early attention to palliative care improves outcomes for patients with cancer

• But….this telephone-based intervention was not sufficient for impacting health care utilization or delivery of end-of-life care.
In Person Outpatient Early Palliative Care

• In-person palliative care with physician or advanced practice provider at least monthly.
  • MGH Model “early integrated palliative care”
    Patients with newly diagnosed incurable cancer receive palliative care until death.
  • Zimmermann Canadian Study
    Patients with a physician estimated limited life expectancy (6-24 months) receive a four-month palliative care intervention.

• Involvement of palliative care when admitted to the hospital.
Operationalizing the MGH Early Integrated Palliative Care Model

• Palliative care visits conducted by physician or advanced practice nurse.

• Palliative care was not manualized, although care followed National Quality Forum guidelines.

• Palliative care visits occurred on the same day as oncology visits.
  • Palliative care visits often take place in the infusion room.
  • Occasionally palliative care and oncology clinicians saw patients in the same room at the same time (“joint visits”).

• Telephone calls as needed to maintain monthly contact
Randomized Trial of Early Integrated Palliative Care in Patients with Metastatic Lung Cancer

150 patients within 8 weeks of diagnosis of metastatic NSCLC with an ECOG PS 0-2

Integrated care
- Monthly palliative care visits weeks in conjunction with oncology visits

Standard care
- Palliative care visits only upon request

Study Measures

Patient-reported measures
1. Quality of life
2. Mood
3. Prognostic awareness

Health service utilization
1. Documentation of resuscitation preferences
2. Hospice utilization
3. Chemotherapy administration

Temel NEJM 363(8) 2010
Lung Cancer Trial – Patient-Reported Outcomes

Quality of life

Depression and Anxiety

Temel NEJM 363 (8) 2010
Lung Cancer Trial – Prognostic Awareness

My cancer is curable: Yes or No

Palliative care v Standard care
82.5% v 59.6%, p=0.02

Temel JCO 29 (17) 2011
### Lung Cancer Trial - Health Service Utilization

<table>
<thead>
<tr>
<th>Variable</th>
<th>Standard Care</th>
<th>Early Palliative Care</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Documented Code Status</td>
<td>11/39 (28)</td>
<td>18/34 (53)</td>
<td>0.05</td>
</tr>
<tr>
<td>Hospice Care</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Received hospice care</td>
<td>44/67 (66)</td>
<td>44/62 (71)</td>
<td>0.57</td>
</tr>
<tr>
<td>Length of Stay &gt; 7 days</td>
<td>21/63 (33)</td>
<td>36/60 (60)</td>
<td>0.004</td>
</tr>
<tr>
<td>Median days</td>
<td>9.5 (1-268)</td>
<td>24 (2-116)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

IV chemo within 60 DOD: 46% vs 24% p=0.01

Greer JCO 30 (4) 2012
Integrate PC Trial

350 patients within 8 weeks of diagnosis of advanced/ incurable lung and non-colorectal GI cancers with an ECOG PS 0-2 (and their family caregivers)

**Integrated care**
- Palliative care visits every 3-4 weeks in conjunction with oncology visits

**Standard care**
- Palliative care visits only upon request

**Study Measures**

**Patient-reported measures**
1. Quality of life
2. Mood
3. Prognostic awareness
4. Coping

**Family-reported measures**
1. Quality of life
2. Mood
3. Prognostic awareness

**Health service utilization**
1. Chemotherapy administration
2. Documentation of resuscitation preferences
3. Hospital utilization

Temel JCO 35 (8) 2017
Integrate PC Trial – Coping and EOL Communication

<table>
<thead>
<tr>
<th>Measure</th>
<th>Usual Care</th>
<th>Early PC</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>“Knowing about prognosis has been very/extremely helpful for”</td>
<td>89.8%</td>
<td>96.5%</td>
<td>0.04</td>
</tr>
<tr>
<td>- Making decisions about treatment</td>
<td>83.6%</td>
<td>97.3%</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>- Coping with the disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>“Discussed wishes about the care you would want to receive if you are dying”</td>
<td>14.5%</td>
<td>30.2%</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

[Temel JCO 35 (8) 2017]
### Table 2. Effect of early integrated palliative care on caregivers’ outcomes at 12 and 24 weeks

<table>
<thead>
<tr>
<th>Sample size</th>
<th>Group assignment</th>
<th>Adjusted mean score</th>
<th>95% CI</th>
<th>Adjusted mean difference</th>
<th>95% CI</th>
<th>Effect size (d)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Week 12 outcomes</strong>&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HADS-Total distress 227</td>
<td>Control</td>
<td>10.48</td>
<td>9.58–11.38</td>
<td>-1.45</td>
<td>-2.76 to -0.15</td>
<td>0.300</td>
<td>.029</td>
</tr>
<tr>
<td></td>
<td>Intervention</td>
<td>9.02</td>
<td>8.09–9.96</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SF-36 PCS n = 228</td>
<td>Control</td>
<td>51.40</td>
<td>49.83–52.98</td>
<td>1.54</td>
<td>-0.74–3.82</td>
<td>0.180</td>
<td>.183</td>
</tr>
<tr>
<td></td>
<td>Intervention</td>
<td>52.94</td>
<td>51.30–54.59</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SF-36 MCS n = 228</td>
<td>Control</td>
<td>45.92</td>
<td>44.25–47.59</td>
<td>1.09</td>
<td>-1.33–3.51</td>
<td>0.119</td>
<td>.376</td>
</tr>
<tr>
<td></td>
<td>Intervention</td>
<td>47.00</td>
<td>45.26–48.74</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Canadian Study

461 patients with stage IV cancer (including hormone refractory breast and prostate) or stage III with poor prognosis and ECOG PS 0-2 with a clinical prognosis of 6-24 months

Early Palliative Care Intervention

Usual Care

Outcome Measures

Patient-reported Measures
1. QOL
2. Symptoms
3. Quality of Life at EOL
4. Satisfaction

Zimmermann Lancet 383(9930) 2014
## Canadian Study – Patient-Reported Outcomes

<table>
<thead>
<tr>
<th>Measure</th>
<th>Intervention (mean change from baseline)</th>
<th>Control (mean change from baseline)</th>
<th>Adjusted Difference (between change)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality of Life (Spiritual)</td>
<td>2.46</td>
<td>-3.95</td>
<td>9.44</td>
<td>0.006</td>
</tr>
<tr>
<td>Quality of Life at End of Life</td>
<td>3.04</td>
<td>-0.51</td>
<td>3.51</td>
<td>0.003</td>
</tr>
<tr>
<td>Symptom Burden</td>
<td>-1.34</td>
<td>3.23</td>
<td>-4.41</td>
<td>0.05</td>
</tr>
<tr>
<td>Satisfaction</td>
<td>3.70</td>
<td>-2.42</td>
<td>6.00</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
Take Home Points From Outpatient In-Person Early Palliative Care Studies

• Similar to the ENABLE intervention, in-person palliative care improves patient’s QOL, mood, and symptom burden.
• Early and longitudinal palliative care involvement improves communication about and delivery of end-of-life care.
• But these care models are complex…. 
400 patients at 10 academic and 10 community Alliance sites within 8 weeks of diagnosis of advanced/incurable lung and non-colorectal GI cancers with an ECOG PS 0-2 (and their family caregivers)

**Integrated care**
- Palliative care contact at least every 4 weeks in conjunction with oncology visits

**Standard care**
- Palliative care visits only upon request

**Study Measures**

**Patient-reported measures**
1. Quality of life
2. Mood
3. Prognostic awareness

**Family-reported measures**
1. Quality of life
2. Mood
3. Prognostic awareness

**Health service utilization**
1. Chemotherapy administration
2. Documentation of resuscitation preferences
3. Hospital utilization

Temel JPM 23 (7) 2020
In addition to experiencing difficulties with intervention delivery, this trial faced challenges with data collection with more than 60% missing data at the primary endpoint of week-24.

### Table 3. Intervention Effects on Change in Outcomes From Baseline to Week 24

<table>
<thead>
<tr>
<th></th>
<th>Early Palliative Care</th>
<th>Usual care</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean change from baseline (SD)</td>
</tr>
<tr>
<td>FACT-G</td>
<td>68</td>
<td>3.80 (15.3)</td>
</tr>
<tr>
<td>HADS-Depression</td>
<td>75</td>
<td>0.37 (3.8)</td>
</tr>
<tr>
<td>HADS-Anxiety</td>
<td>75</td>
<td>−1.23 (3.5)</td>
</tr>
</tbody>
</table>
Inpatient Palliative Care Interventions

In person early palliative care models
Palliative Care for Patients Undergoing Hematopoietic Stem Cell Transplant

160 patients admitted to MGH for autologous or allogeneic hematopoietic transplant and their family caregivers

Palliative Care Intervention
Twice weekly visits during the transplant

Usual Care

Outcome Measures

Patient-reported Outcomes
1. Quality of life
2. Symptom burden
3. Mood
4. Post-traumatic stress

Family-caregiver Outcomes
1. Quality of life
2. Mood

El-Jawahri JAMA 316(20) 2016
Palliative Care for Patients Undergoing Hematopoietic Stem Cell Transplant

El-Jawahri JAMA 316(20) 2016
Long Term Effects of Palliative Care During Transplant

Palliative Care Effects at Six Months Post-Transplant

<table>
<thead>
<tr>
<th>Condition</th>
<th>Intervention</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depression</td>
<td>14.3%</td>
<td></td>
</tr>
<tr>
<td>Post-traumatic stress</td>
<td>7.3%</td>
<td>21.1%</td>
</tr>
</tbody>
</table>

El-Jawahri JCO 35(32) 2017
Palliative Care for Patients with Acute Myeloid Leukemia

160 patients admitted to four tertiary care hospitals with newly diagnosed AML receiving intensive chemotherapy

Palliative Care Intervention
Twice weekly visits during hospitalizations

Usual Care

Outcome Measures

Patient-reported Outcomes
1. Quality of life
2. Symptom burden
3. Mood
4. Post-traumatic stress

End of Life Care Outcomes
1. EOL communication
2. Chemotherapy use
3. Hospice use

El-Jawahri JAMA Oncology 2020 in press
Palliative Care for Patients with Acute Myeloid Leukemia

A Functional Assessment of Cancer Therapy-Leukemia

B Hospital Anxiety and Depression Scale (anxiety)

C Hospital Anxiety and Depression Scale (depression)

D PTSD Checklist-Civilian version

El-Jawahri JAMA Oncology 2020 in press
Palliative Care for Patients with Acute Myeloid Leukemia

<table>
<thead>
<tr>
<th></th>
<th>Usual Care</th>
<th>Palliative Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discussed EOL preferences</td>
<td>40%</td>
<td>75%</td>
</tr>
<tr>
<td>Chemotherapy in last month of life</td>
<td>34.90%</td>
<td>65.90%</td>
</tr>
<tr>
<td>Hospice use</td>
<td>36.60%</td>
<td>74.40%</td>
</tr>
<tr>
<td>Hospitalization in last week of life</td>
<td>83.30%</td>
<td></td>
</tr>
</tbody>
</table>

Discussed EOL preferences, Chemotherapy in last month of life, Hospice use, Hospitalization in last week of life.
Take Home Points From Inpatient Palliative Care Studies

• Palliative care improves outcomes for patients with hematologic malignancies being treated with curative intent.
• Even brief/short term exposure to palliative care can have an impact on late outcomes.
“Status of the Field”

1. Transitioning palliative care from the hospital to the outpatient setting is an effective care model and improves the experience and outcomes of patients with serious cancers.

2. Involving palliative care in the care of hospitalized patients receiving intensive cancer treatments with curative intent, such as patients with acute leukemia or those undergoing hematopoietic stem cell transplant, improves their experience and outcomes.
The End.
Not So Fast….

- Lack of data on the nature, timing, and dose of palliative care across populations.
- Cancer care is changing rapidly so even with data across populations, does that data still apply?
- Inadequate space and resources for palliative care within cancer centers.
- Not enough palliative care clinicians to care for all patients with serious cancers.
What is Palliative Care Doing?

Palliative care visit focus during the first 24 weeks of study:

- Symptoms: 74.7%
- Coping: 70.2%
- Rapport: 44.4%
- Illness Understanding: 38.4%
- Treatment Decisions: 16.3%
- Advance-Care Planning: 14.2%
- Disposition: 2.1%

Temel JCO 35(8) 2017
Practice of Early Integrated Outpatient Palliative Care

Rapport
Symptoms
Coping
Illness Understanding
Advance Care Planning
Treatment Decisions
Disposition

1st (n = 158)
2nd (n = 149)
3rd (n = 140)
Middle (n = 136)
3rd-to-last (n = 125)
2nd-to-last (n = 127)
Last (n = 128)

Palliative Care Visit

Hoerger JCO 36 (11) 2018
Importance of Coping in Improving QOL

Greer, Jacobs JCO 36 (1) 2018
Importance of Coping in Improving Depression

Greer, Jacobs JCO 36 (1) 2018
But Different Populations May Need Different Palliative Care “Things”

- Monthly outpatient visits from diagnosis until may not be the right timing and interval for all patients with serious cancers.
- A focus on coping may not be the most important element of palliative care for all patients.
Palliative Care in the Context of a Rapidly Changing Field of Oncology

• Since these palliative care trials were conducted, there have been significant changes in cancer therapeutics which have impacted patients’ quality of life and survival.
  • Some groups of patients with advanced cancer are not treated with chemotherapy throughout their illness.
    • Most of the time, novel therapies such as immunotherapy and targeted therapy have less side effects than chemotherapy.
  • Subpopulations of patients with advanced cancer are living significantly longer.
But Novel Therapies Bring About Novel Palliative Care Challenges

Timeline of Treatment

Effect of Therapy

Before Lorlatinib  
Response to Lorlatinib  
Resistance to Lorlatinib  
Response to Crizotinib

Shaw  NEJM 374(1) 2016
Implications of Novel Therapies on the Practice of Palliative Care

- Palliative care may need to focus less on addressing physical symptoms.
- Palliative care will likely need to play a significant role helping patients and their families manage prognostic uncertainty and the distress associated with it.
- Palliative care will likely need to play a greater role in end-of-life decision making.
Patient-Centered Palliative Care

Patients with serious cancers
Patient-Centered Palliative Care

- **Patients with serious cancers**
  - Low symptom burden and low mortality
    - Palliative care focused on EOL communication once prognosis is poor
  - High symptom burden but curable disease
    - Palliative care during high symptom periods
  - Prolonged periods with low symptom burden
    - Identify triggers for palliative care (i.e., hospitalization or cancer progression)

- **High symptom burden and mortality**
  - Early and intensive longitudinal palliative care
Addressing Inadequate Palliative Care Staffing and Resources

1. Determine whether increasing “primary palliative care” skills in oncology can achieve similar results as specialty palliative care.

2. Develop less resource intensive palliative care delivery models.
   - Utilize novel technologies to provide services
   - Triage services to those who need it most
Serious Illness Communication

Table 3. Achievement of Goal-Concordant Care and Peacefulness Near the End of Life

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Intervention Arm</th>
<th>Control Arm</th>
<th>Differences (95% CI)*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>Mean (95% CI)</td>
<td>Median (95% CI)</td>
</tr>
<tr>
<td>Goal-concordant care</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of goals met</td>
<td>38</td>
<td>1.4 (1.0 to 1.7)</td>
<td>0.8 (0.6 to 1.1)</td>
</tr>
<tr>
<td>Sensitivity analysis</td>
<td>29</td>
<td>1.3 (1.0 to 1.6)</td>
<td>0.8 (0.5 to 1.1)</td>
</tr>
<tr>
<td>PEACE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PA scale</td>
<td>47</td>
<td>16.9 (16.1 to 17.6)</td>
<td>NA</td>
</tr>
<tr>
<td>SI scale</td>
<td>44</td>
<td>14.0 (12.9 to 15.1)</td>
<td>NA</td>
</tr>
</tbody>
</table>

Figure 2. Outcomes of Assessments of Therapeutic Alliance, Anxiety, and Depression

- **Therapeutic alliance**
- **Anxiety**
- **Depression**

Bernacki JAMA IM 179 (6) 2019
JUMPSTART Communication Intervention

Table 3. Effect of the Intervention on Patients’ Symptoms of Depression and Anxiety

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Patients/Clinics, No.</th>
<th>Mean Value for Psychological Symptoms (95% CI) at Follow-up</th>
<th>$\beta$ (95% CI)$^d$</th>
<th>$P$ Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depression Symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 Months after target visit</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-Indicator latent variable$^a$</td>
<td>262/113</td>
<td>0.20 (−0.02 to 0.42)</td>
<td>0.26 (−0.04 to 0.55)</td>
<td>−0.10 (−0.33 to 0.12)</td>
</tr>
<tr>
<td>Standard PHQ-8 composite score$^b$</td>
<td>359/119</td>
<td>4.88 (4.23 to 5.54)</td>
<td>5.92 (5.19 to 6.66)</td>
<td>0.26 (−0.57 to 1.10)</td>
</tr>
<tr>
<td>6 Months after target visit</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-Indicator latent variable$^a$</td>
<td>262/113</td>
<td>0.24 (0.07 to 0.42)</td>
<td>0.40 (0.11 to 0.69)</td>
<td>0.21 (−0.04 to 0.46)</td>
</tr>
<tr>
<td>Standard PHQ-8 Composite Score$^b$</td>
<td>314/118</td>
<td>4.84 (4.17 to 5.51)</td>
<td>5.927 (5.05 to 6.81)</td>
<td>0.45 (−0.48 to 1.37)</td>
</tr>
<tr>
<td>Anxiety Symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 Months after target visit</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-Indicator latent variable$^a$</td>
<td>277/119</td>
<td>0.22 (0.01 to 0.43)</td>
<td>0.28 (−0.04 to 0.60)</td>
<td>−0.03 (−0.23 to 0.16)</td>
</tr>
<tr>
<td>Standard GAD-7 composite score$^b$</td>
<td>366/122</td>
<td>3.00 (2.44 to 3.57)</td>
<td>3.26 (2.64 to 3.89)</td>
<td>0.04 (−0.95 to 1.03)</td>
</tr>
<tr>
<td>6 Months after target visit</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-Indicator latent variable$^a$</td>
<td>277/119</td>
<td>0.21 (−0.05 to 0.47)</td>
<td>0.30 (0.00 to 0.59)</td>
<td>−0.04 (−0.25 to 0.16)</td>
</tr>
<tr>
<td>Standard GAD-7 Composite Score$^b$</td>
<td>327/119</td>
<td>3.08 (2.44 to 3.72)</td>
<td>3.375 (2.67 to 4.08)</td>
<td>−0.11 (−1.20 to 1.00)</td>
</tr>
</tbody>
</table>

Curtis, JAMA IM 178 (7) 2018
Primary Palliative Care

• With training and support, there should not be a significant downside to oncology clinicians doing what they can to deliver “palliative care”.

• We have mixed results on “serious illness communication” improving EOL outcomes for patients but this field is in its infancy and I feel optimistic that as our experience with these interventions grow, these will be effective interventions.

• We do not yet have data on primary palliative care for outcomes other than EOL care but hopefully that is forthcoming.
Less Intensive Palliative Care Delivery Models
Patients with advanced NSCLC (N=1250) [and their caregivers]

Baseline participant-reported measures

Randomization

Telehealth early palliative care (monthly telehealth visits)

In-person early palliative care (monthly in-person visits)

Participant-reported measures every 3 months

Caregiver after death assessment

Utilizing HIPAA compliant video technology to provide face to face care
• “Stepped care” is an evidence-based method to increase access to and efficiency of health care services.

• With stepped care, all patients receive care low intensity treatment with more intensive intervention reserved for those who have greater needs.
• The role of early involvement of palliative care for patients with newly diagnosed poor prognosis cancer or those undergoing intensive inpatient treatment is now established.

• While the data from published trials is compelling, implementing these care models can be challenging.

• We must focus our research efforts on how to develop more patient-centered and scalable palliative care models to increase access to this essential aspect of care for patients with serious cancers.
Thank you

- Massachusetts General Hospital Cancer Center
  - Cancer Outcomes Research and Education Program
  - Center for Thoracic Oncology
  - Center for Psychiatric Oncology and Behavioral Science
  - Division of Palliative Care
- National Institute of Nursing Research
- National Cancer Institute
- Patient Centered Outcomes Research Institute
- American Cancer Society
- National Palliative Care Research Center